- Medicine Name: Rezurock
- Generic Name: Belumosudil
- Dosage Form & Strength: Tablet: 200 mg
- Manufactured By: Kadmon Holdings, Inc.
Rezurock is a kinase inhibitor used for the treatment of adult and pediatric patients aged 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least a couple of prior lines of systemic therapy.
Recommended Dosage: The recommended dose is 200 mg given by mouth (orally) once daily until progression of chronic graft-versus-host disease that needs new systemic therapy. Swallow rezurock tablets whole. It is not advisable to cut, crush, or chew tablets. Take all the dosage with a meal at approximately the same time each day.
In case a dose is missed/skipped, the patient should not take extra doses to make up the missed dose.
Therapy with Rezurock has not been studied in those with pre-existing severe renal/hepatic impairment. For all those with pre-existing severe renal/hepatic impairment, risks and potential benefits must be considered before starting therapy with Rezurock.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.